Brief: Fusen Pharmaceutical Sees Loss Attributable With A Range From RMB35 Mln To RMB43 Mln For FY
15/03/2024 13:16
March 15 (Reuters) - Fusen Pharmaceutical Co Ltd
1652.HK :
* SEES LOSS ATTRIBUTABLE WITH A RANGE FROM RMB35 MILLION TO
RMB43
MILLION FOR FY
* EXPECTED RESULT DUE TO INCREASED INVESTMENT IN RESEARCH
AND
DEVELOPMENT FOR FUTURE NEW PRODUCT PIPELINES, OTHERS
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA